$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
What are the side effects of sparsentan?
2025-10-19 11:44:20
Check Details
What are the contraindications for sparsentan (which drugs cannot be taken together with it)?
2025-10-19 11:44:20
Check Details
What is the difference between sparsentan and ambrisentan?
2025-10-19 11:44:20
Check Details
What are the effects and functions of sparsentan?
2025-10-19 11:44:20
Check Details
What is the effectiveness of the orphan drug Sparsentan in the treatment of IgA nephropathy?
2025-10-19 11:44:20
Check Details
Does sparsentan have any side effects in treating IgA nephropathy
2025-10-19 11:44:20
Check Details
Can spaxentan cause liver toxicity?
2025-10-19 11:44:20
Check Details
What serious side effects can spaxentan cause?
2025-10-19 11:44:20
Check Details
Efficacy and side effects of budesonide sustained-release capsules
2025-10-19 11:44:20
Check Details
Can sparsentin treat proteinuria?
2025-10-19 11:44:20
Check Details
How effective is sparsentan in treating urinary protein
2025-10-19 11:44:20
Check Details
What is the correct usage and dosage of sparsentan?
2025-10-19 11:44:20
Check Details
1
2
...
4223
4224
4225
4226
4227
4228
4229
...
10231
10232
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Bedaquiline Drug Interactions: CYP3A4 and QT Prolongation Risks
2
Acalabrutinib Dosing Guide: Dosage, Duration and Precautions
3
Epclusa (Sofosbuvir/Velpatasvir) Pan-Genotypic HCV Treatment: Mechanism, Efficacy, and Dosing
4
Laos Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) Generic Guide: Efficacy, Regimen Selection, and Precautions
5
Finerenone: Indications, Dosing Strategy, and Combination Therapy
6
Selpercatinib: Dosing and Administration Essentials of an Oral RET Inhibitor
7
Enasidenib: A Targeted IDH2 Inhibitor for Acute Myeloid Leukemia
8
Alpelisib: From Breast Cancer to PIK3CA-Related Overgrowth Spectrum
9
Ponatinib in Chronic Myeloid Leukemia: 5-Year Results from the OPTIC Trial
10
Erdafitinib Oral Tablets: Strengths, Packaging, and Dose Adjustment
11
Capmatinib (Tabrecta): Oral Targeted Therapy for MET Exon 14 Skipping-Mutated NSCLC
12
Amivantamab Plus Lazertinib: A Chemotherapy-Free First-Line Option in EGFR-Mutated NSCLC